INmune Bio Inc (NASDAQ:INMB) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 18,000 shares, a decline of 32.6% from the September 30th total of 26,700 shares. Based on an average trading volume of 31,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the shares of the company are sold short.
Shares of INMB traded down $0.13 during trading hours on Tuesday, hitting $4.45. The stock had a trading volume of 12,000 shares, compared to its average volume of 19,914. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.94 and a current ratio of 20.94. The firm has a 50-day moving average price of $4.87 and a 200 day moving average price of $7.83. INmune Bio has a fifty-two week low of $3.51 and a fifty-two week high of $11.50.
INmune Bio (NASDAQ:INMB) last posted its earnings results on Friday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09). Equities research analysts anticipate that INmune Bio will post -0.65 earnings per share for the current year.
In other INmune Bio news, Director Scott Juda acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $30,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have acquired 12,918 shares of company stock valued at $77,109. Company insiders own 67.67% of the company’s stock.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. lifted its position in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,048 shares of the company’s stock after purchasing an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.35% of the company’s stock.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Further Reading: Intrinsic Value
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.